Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection

被引:134
|
作者
Theil, FP [1 ]
Guentert, TW [1 ]
Haddad, S [1 ]
Poulin, P [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, Nonclin Drug Safety, Pharma Res, CH-4070 Basel, Switzerland
关键词
drug discovery; drug development; partition coefficients; PBPK modeling; pharmacokinetics; toxicokinetics; QSAR;
D O I
10.1016/S0378-4274(02)00374-0
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The present paper proposes a modeling and simulation strategy for the prediction of pharmacokinetics (PK) of drug candidates by using currently available in silico and in vitro based prediction tools for absorption, distribution, metabolism and excretion (ADME). These methods can be used to estimate specific ADME parameters (such as rate and extent of absorption into portal vein, volume of distribution, metabolic clearance in the liver). They can also be part of a physiologically based pharmacokinetic (PBPK) model to simulate concentration-time profiles in tissues and plasma resulting from the overall PK after intravenous or oral administration. Since the ADME prediction tools are built only on commonly generated in silico and in vitro data, they can be applied already in early drug discovery, prior to any in vivo study. With the suggested methodology, the following advantages of the mechanistic PBPK modeling framework can now be utilized to explore potential clinical candidates already in drug discovery: (i) prediction of plasma (blood) and tissue PK of drug candidates prior to in vivo experiments, (ii) supporting a better mechanistic understanding of PK properties, as well as helping the development of more rationale PK-PD relationships from tissue kinetic data predicted, and hence facilitating a more rational decision during clinical candidate selection, and (iii) the extrapolation across species, routes of administration and dose levels. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 49
页数:21
相关论文
共 50 条
  • [31] Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions
    Britz, Hannah
    Hanke, Nina
    Taub, Mitchell E.
    Wang, Ting
    Prasad, Bhagwat
    Fernandez, Eric
    Stopfer, Peter
    Nock, Valerie
    Lehr, Thorsten
    PHARMACEUTICAL RESEARCH, 2020, 37 (12)
  • [32] Incorporation of in vitro drug metabolism data into physiologically-based pharmacokinetic models
    Houston, JB
    Carlile, DJ
    TOXICOLOGY IN VITRO, 1997, 11 (05) : 473 - 478
  • [33] Physiologically-based pharmacokinetic models to predict drug exposure during pregnancy
    Ait-Chikh, Celia
    Page, Guylene
    Thoreau, Vincent
    ANNALES PHARMACEUTIQUES FRANCAISES, 2024, 82 (02): : 236 - 242
  • [34] Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models
    Abduljalil, Khaled
    Badhan, Raj K. Singh
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2020, 47 (04) : 319 - 340
  • [35] Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions
    Rytkonen, Jaana
    Ranta, Veli-Pekka
    Kokki, Merja
    Kokki, Hannu
    Hautajarvi, Heidi
    Rinne, Valtteri
    Heikkinen, Aki T.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2020, 41 (1-2) : 72 - 88
  • [36] Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience
    Karen S. Blesch
    Ronald Gieschke
    Yuko Tsukamoto
    Bruno G. Reigner
    Hans U. Burger
    Jean-Louis Steimer
    Investigational New Drugs, 2003, 21 : 195 - 223
  • [37] Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: The capecitabine experience
    Blesch, KS
    Gieschke, R
    Tsukamoto, Y
    Reigner, BG
    Burger, HU
    Steimer, JL
    INVESTIGATIONAL NEW DRUGS, 2003, 21 (02) : 195 - 223
  • [38] Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and its Regulatory Utility to Support Oral Drug Product Development and Harmonization
    Cheng, Yi-Hsien
    Thomas, Sherin
    Tsang, Yu Chung
    Almeida, Susana
    Ashraf, Muhammad
    Fotaki, Nikoletta
    Heimbach, Tycho
    Patel, Nikunjkumar
    Shah, Harshil
    Jiang, Xiaojian
    Kim, Myong-Jin
    Moody, Rebecca
    Rostami-Hodjegan, Amin
    Singh, Romi
    Zhao, Liang
    Babiskin, Andrew
    Wu, Fang
    PHARMACEUTICAL RESEARCH, 2025,
  • [39] Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug–Drug Interactions Involving Enzyme Modulation
    Chia-Hsiang Hsueh
    Vicky Hsu
    Yuzhuo Pan
    Ping Zhao
    Clinical Pharmacokinetics, 2018, 57 : 1337 - 1346
  • [40] Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
    Yu, Zhiheng
    Lei, Zihan
    Yao, Xueting
    Wang, Hengbang
    Zhang, Miao
    Hou, Zhe
    Li, Yafen
    Zhao, Yangyu
    Li, Haiyan
    Liu, Dongyang
    Zhai, Yifan
    FRONTIERS IN PHARMACOLOGY, 2022, 13